ServareGMP
ServareGMP is a nonprofit biotechnology public benefit corporation focused on the development and manufacturing of low-cost biologic medicines, such as monoclonal antibodies, for infectious and neglected diseases affecting vulnerable populations. The organization utilizes advanced bioprocessing methods, continuous manufacturing, and open-source technology transfer to expand access to biotherapeutics in low- and middle-income countries. Its efforts address cost reduction, local capacity building, and equitable distribution through collaborations with global health entities and an emphasis on outbreak response and diseases impacting disadvantaged or displaced communities.
Industries
N/A
ServareGMP
Products
A long half-life engineered monoclonal antibody targeting Vibrio cholerae O1 and O139 serotypes lipopolysaccharide, developed for pre-exposure prophylaxis in outbreak settings, optimized for subcutaneous formulation, stability, and low-cost mass production.
A long half-life engineered monoclonal antibody targeting Vibrio cholerae O1 and O139 serotypes lipopolysaccharide, developed for pre-exposure prophylaxis in outbreak settings, optimized for subcutaneous formulation, stability, and low-cost mass production.
Expertise Areas
- Bioprocess development for monoclonal antibodies
- Continuous and fed-batch biologics manufacturing
- Therapeutic and prophylactic antibody development
- Low-cost biologics for infectious and neglected diseases
Key Technologies
- Continuous bioprocessing
- High-titer CHO cell lines
- Single-use bioreactor platforms
- Fed-batch and perfusion culture
Key People
Executive Director
Chief Scientific Officer
Chief Financial Officer
Board of Directors
Board of Directors
Board of Directors
Executive Director
Chief Scientific Officer
Chief Financial Officer
Board of Directors
Board of Directors
Board of Directors
News & Updates
Details scientific advances and economic modeling for deploying low-cost monoclonal antibodies to low- and middle-income countries using innovative biomanufacturing.
Trials will evaluate safety and tolerability of a monoclonal antibody designed to provide immediate protection against Nipah virus, supported by CEPI with funding for pre- and post-exposure prophylaxis studies.
Development of an ultra low-cost monoclonal antibody for cholera, aimed at displaced populations and regions with high cholera incidence.
Details scientific advances and economic modeling for deploying low-cost monoclonal antibodies to low- and middle-income countries using innovative biomanufacturing.
Trials will evaluate safety and tolerability of a monoclonal antibody designed to provide immediate protection against Nipah virus, supported by CEPI with funding for pre- and post-exposure prophylaxis studies.
Development of an ultra low-cost monoclonal antibody for cholera, aimed at displaced populations and regions with high cholera incidence.